

Resource Summary Report

Generated by ASWG on Aug 9, 2026

Recombinant Anti-p38 alpha/MAPK14 antibody [E229]

RRID:AB_3083680

Type: Antibody

Proper Citation

Abcam Cat# ab170099, RRID:AB_3083680

Antibody Information

URL: http://antibodyregistry.org/AB_3083680

Proper Citation: Abcam Cat# ab170099, RRID:AB_3083680

Target Antigen: p38 alpha/MAPK14

Host Organism: rabbit

Clonality: recombinant monoclonal

Comments: Applications: Flow Cyt (Intra), WB, ICC/IF, IP

Antibody Name: Recombinant Anti-p38 alpha/MAPK14 antibody [E229]

Description: This recombinant monoclonal targets p38 alpha/MAPK14

Target Organism: rat, mouse, human

Clone ID: E229

Antibody ID: AB_3083680

Vendor: Abcam

Catalog Number: ab170099

Record Creation Time: 20250820T015746+0000

Record Last Update: 20250820T122004+0000

Ratings and Alerts

No rating or validation information has been found for Recombinant Anti-p38 alpha/MAPK14 antibody [E229].

No alerts have been found for Recombinant Anti-p38 alpha/MAPK14 antibody [E229].

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 4 mentions in open access literature.

Listed below are recent publications. The full list is available at [ASWG](#) .

Ding R, et al. (2025) Astragaloside IV alleviates hypoxic pulmonary hypertension by inhibiting RELM-?? to reduce PINK1/Parkin-mediated mitophagy in pulmonary artery smooth muscle cells (PASMCs). British journal of pharmacology.

Li Y, et al. (2025) Nrf2/Nlrp3 signaling in aging BMSCs: Traf6 intervention as a novel approach to osteoporosis treatment. Redox biology, 86, 103804.

Zhao Y, et al. (2025) High glucose induces osteoblasts ferroptosis via the TXNIP/Trx-1/GPX4 pathway in type 2 diabetic osteoporosis. European journal of medical research, 31(1), 163.

Hong L, et al. (2025) TLR2 activates AP-1 to facilitate CTGF transcription and stimulate doxorubicin-induced myocardial injury. British journal of pharmacology, 182(13), 2897.